Welcome to our dedicated page for Fresenius Med Cr SEC filings (Ticker: FMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fresenius Medical Care AG (FMS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the New York Stock Exchange. Fresenius Medical Care files reports on Form 6-K under the Securities Exchange Act of 1934, furnishing press releases, financial figures, and other information that it discloses in its home market.
In these filings, investors can review quarterly financial updates that include revenue, operating income, net income, earnings per share, cash flow, and net leverage ratio, along with reconciliations of non-GAAP or non-IFRS measures such as EBITDA, free cash flow, and constant-currency results. The company’s 6-Ks also describe segment performance across Care Delivery, Care Enablement, and Value-Based Care, highlighting organic revenue growth, margins, and the impact of portfolio optimization and transformation programs like FME25+.
Fresenius Medical Care uses Form 6-K to furnish information on strategic initiatives and capital allocation decisions. Examples include disclosures related to its initial EUR 1 billion share buyback program, including tranches, timing, and regulatory notices furnished as convenience translations of European market abuse regulation disclosures. Filings may also reference bond issuances, debt redemption, and elements of the company’s capital structure.
Other 6-K submissions include press releases on leadership changes within the Management Board, updates on the FME Reignite strategy, and information about investments in entities such as Interwell Health. These documents help investors understand how Fresenius Medical Care manages its integrated dialysis business, transformation efforts, and value-based care activities.
On Stock Titan, SEC filings for FMS are supplemented with AI-powered summaries that highlight key figures, segment trends, and notable disclosures, helping users navigate lengthy documents more efficiently. Real-time updates from EDGAR ensure that new 6-Ks and other relevant filings appear promptly, while structured access to filings supports deeper analysis of Fresenius Medical Care’s financial performance, capital allocation, and strategic direction over time.
Fresenius Medical Care, a leading global provider of dialysis products and services, has filed its Annual Report on Form 20-F for fiscal year 2025 with the U.S. Securities and Exchange Commission. The full report, including audited consolidated financial statements, is available on the company’s website and from the SEC.
The company treats individuals with renal diseases through a network of 3,601 dialysis clinics serving approximately 292,000 patients and supports around 4.5 million people worldwide who regularly undergo dialysis. Printed copies of the 20-F can be requested free of charge from the investor relations department.
Fresenius Medical Care AG files its annual Form 20-F, outlining its global kidney care business and risk profile. The company reports 279,288,885 ordinary shares outstanding as of the period end, and notes that Fresenius SE held 76,814,594 shares, or 26.2%, as of February 13, 2026.
The report explains a three-segment structure: Care Enablement (products and manufacturing), Care Delivery (dialysis and related services), and a new Value-Based Care segment created June 1, 2025, which manages risk-based kidney care contracts under IFRS 15 and IFRS 17. It also describes the 2023 legal conversion from a partnership limited by shares into a stock corporation and Fresenius SE’s ongoing influence via board appointment rights and trademark licensing.
Extensive risk disclosures highlight dependence on U.S. Medicare and Medicaid (Medicare and Medicaid contributed about 16% of consolidated revenue in 2025, with additional Medicaid and other government sources representing 4.7% of U.S. patient service revenue), exposure to healthcare reform and reimbursement cuts, regulatory and compliance requirements, cyber-security threats, ESG and supply-chain obligations, labor shortages, macroeconomic pressures, and €10,795 M of consolidated debt versus €14,283 M of shareholders’ equity as of December 31, 2025.
Fresenius Medical Care reported a strong 2025, with revenue of €19.6 billion and operating income up 31% to €1.83 billion. On an adjusted basis, operating income rose 23% to €2.21 billion, lifting the margin to 11.3% from 9.3%.
Net income attributable to shareholders jumped 82% to €978 million, and adjusted net income rose 38% to €1.25 billion. Basic EPS increased to €3.36, or €4.28 excluding special items. Operating cash flow grew 12% to €2.68 billion and free cash flow reached €1.78 billion.
The company cut net debt to €9.2 billion and reduced its net leverage ratio to 2.5x. Management proposes a €1.49 dividend per share, about 33% of adjusted net income, and is executing a €1.0 billion share buyback while targeting further FME25+ cost savings and modest operating income growth through 2028.
Fresenius Medical Care AG reports interim operating updates and segment changes. As of June 1, 2025, the company created a new Value‑Based Care segment, recognizing full‑risk arrangements under IFRS 17 with premiums and claim costs presented separately. For the nine months ended September 30, 2025, 16% of consolidated revenue was attributable to U.S. federally funded programs.
Capital efficiency remained modest: ROIC was 4.1%, or 4.9% excluding Legacy Portfolio Optimization costs, based on NOPAT of €1,101 M and average invested capital of €27,150 M. Total assets were €30,887 M and invested capital €25,471 M as of September 30, 2025.
Regulatory dynamics continue to influence U.S. operations. CMS proposed to terminate the mandatory ETC model on December 31, 2025; 971 U.S. facilities (about 35%) are currently in ETC regions and the program to date produced a net positive payment adjustment. The company participates in 21 KCEs, with approximately 52,000 patients aligned as of September 2025, reflecting scale in value‑based kidney care.
Fresenius Medical Care AG furnished a Form 6-K announcing its third quarter results for the period ended September 30, 2025. The submission includes a press release (Exhibit 99.1) and accompanying financial figures (Exhibit 99.2).
The company highlights non-GAAP measures alongside IFRS results, including EBITDA, free cash flow, net leverage ratio (net debt to adjusted EBITDA), constant-currency metrics, and results adjusted for special items, with reconciliations provided in the exhibits. The exhibits are furnished, not filed.